{"id":"cyproheptadine","rwe":[],"_fda":{"id":"f33fcf42-0b48-eed9-e053-2995a90abefb","set_id":"029ed3b6-175e-4a1a-81ed-350bff5f6167","openfda":{"upc":["0362135236908"],"unii":["NJ82J0F8QC"],"route":["ORAL"],"rxcui":["866144"],"spl_id":["f33fcf42-0b48-eed9-e053-2995a90abefb"],"brand_name":["Cyproheptadine Hydrochloride"],"spl_set_id":["029ed3b6-175e-4a1a-81ed-350bff5f6167"],"package_ndc":["62135-236-90"],"product_ndc":["62135-236"],"generic_name":["CYPROHEPTADINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CYPROHEPTADINE HYDROCHLORIDE"],"manufacturer_name":["Chartwell RX, LLC"],"application_number":["ANDA088212"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS Children - Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions, and death. Antihistamines may diminish mental alertness conversely particularly in the young child they may occasionally produce excitation. CNS Depressants - Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. Activities Requiring Mental Alertness - Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients."],"pregnancy":["PREGNANCY Pregnancy Category B: Reproduction studies have been performed in rabbits, mice, and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see CONTRAINDICATIONS ). Pediatric Use: Safety and effectiveness in children below the age of two years have not been established. (See CONTRAINDICATIONS , Newborn or Premature infants , and WARNINGS , Children .)"],"overdosage":["OVERDOSAGE: Antihistamine overdosage reactions may vary from central nervous system depression to stimulation, especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur. If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac. If patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken, especially in infants and children. When life threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response, and recurrence after response. (See package circulars for physostigmine products). Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content. Stimulants should not be used. Vasopressors may be used to treat hypotension. The oral LD 50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively."],"description":["DESCRIPTION: Cyproheptadine HCl, is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a while to slightly yellowish, crystalline, solid. with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo (a, d) cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C 21 H 21 NHC1. and the structural formula of the anhydrous salt is: Cyproheptadine hydrochloride is available in 4 mg tablets. Each tablet contains: Active Ingredient: Cyproheptad1ne Hydrochloride ...................... 4 mg Each tablet contains: Inactive Ingredients: Colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn), stearic acid. image description"],"precautions":["PRECAUTIONS General: Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with History of bronchial asthma. Increased intraocular pressure, Hyperthyroidism, Cardiovascular disease, Hypertension. Information for Patients: Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. Drug Interactions: MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term carcinogenic studies have not been done with cyproheptadine. Cyproheptadine had no effect on fertility in a two-litter study in rats or a two generation study in mice at about 10 times the human dose. Cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts in vitro ; high doses (10- 4 M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth."],"how_supplied":["HOW SUPPLIED: Each tablet contains 4 mg of cyproheptadine hydrochloride, are white to off-white, round, flat faced, beveled edge tablets debossed with “CE 73” on one side and a score on other side. They are supplied as follows: bottles of 90 count, NDC 62135-236-90. Dispensing Information: Dispense in tight containers as defined by the USP/NF. Caution: Federal law prohibits dispensing without prescription. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured for: Chartwell RX, LLC Congers, NY 10920 Telephone Number-1-845-232-1683 L70791 Rev. 01/2023"],"effective_time":"20230127","adverse_reactions":["ADVERSE REACTIONS Adverse reactions which have been reported with the use of antihistamines are as follows: Central Nervous System: Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness. Integumentary: Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity. Special Senses: Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus. Cardiovascular: Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock. Hematologic: Hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia. Digestive System: Dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice. Genitourinary: Urinary frequency, difficult urination, urinary retention, early menses. Respiratory: Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness. Miscellaneous: Fatigue, chills, headache, increased appetite/weight gain."],"contraindications":["CONTRAINDICATIONS Newborn or Premature Infants: This drug should not be used in newborn or premature infants. Nursing Mothers: Because of the higher risk of antihistamines for infants generally, and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Other Conditions: Hypersensitivity to cyproheptadine and other drugs of similar chemical structure. Monoamine oxidase inhibitor therapy (see DRUG INTERACTIONS ). Angle-closure glaucoma. Stenosing peptic ulcer. Symptomatic prostatic hypertrophy. Bladder neck obstruction. Pyloroduodenal obstruction, elderly, debilitated patients."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY: Cyproheptadine HCI is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appears to compete with serotonin and histamine, respectively, for receptor sites. Pharmacokinetics and Metabolism: After a single 4 mg oral dose of 14C-labeled cyproheptadine HCl normal subjects given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No significant difference in the mean urinary excretion exists between the tablet and syrup formulations. No detectable amounts of unchanged drug were present in the urine of patients of chronic 12-20 mg daily doses of cyproheptadine syrup. The principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency."],"indications_and_usage":["INDICATIONS AND USAGE: Perennial and seasonal allergic rhinitis, Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. Children: The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m 2 ). In small children for whom the calculation of the dosage based upon body size is important, it may be necessary to use cyproheptadine syrup to permit accurate dosage. Age 2 to 6 years: The usual dose is 2 mg (1/2 tablet) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day. Age 7 to 14 years: The usual dose is 4 mg (1 tablet) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day. Adults: The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg, a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (1 tablet) three times a day and adjusted according to the size and response of the patient."],"spl_product_data_elements":["Cyproheptadine Hydrochloride Cyproheptadine Hydrochloride SILICON DIOXIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN STEARIC ACID CYPROHEPTADINE HYDROCHLORIDE CYPROHEPTADINE CELLULOSE, MICROCRYSTALLINE Off White CE73"],"package_label_principal_display_panel":["PACKAGE LABEL-PRINCIPAL DISPLAY PANEL Cyproheptadine Hydrochloride Tablets, USP 4 mg NDC 62135-236-90 - 90s Bottle Label image description"]},"tags":[{"label":"cyproheptadine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"R06AX02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Solution","category":"form"},{"label":"Syrup","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Dermatographic urticaria","category":"indication"},{"label":"Itching of skin","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Nasal discharge","category":"indication"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Antipruritics","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"304 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"282 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"239 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"228 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"224 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"223 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"197 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"191 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"187 reports"},{"date":"","signal":"SEROTONIN SYNDROME","source":"FDA FAERS","actionTaken":"178 reports"}],"drugInteractions":[{"url":"/drug/fluoxetine","drug":"fluoxetine","action":"Monitor closely","effect":"May interact with Fluoxetine","source":"DrugCentral","drugSlug":"fluoxetine"},{"url":"/drug/paroxetine","drug":"paroxetine","action":"Monitor closely","effect":"May interact with Paroxetine","source":"DrugCentral","drugSlug":"paroxetine"},{"url":"/drug/sertraline","drug":"sertraline","action":"Monitor closely","effect":"May interact with Sertraline","source":"DrugCentral","drugSlug":"sertraline"}],"commonSideEffects":[{"effect":"Sedation and sleepiness","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Disturbed coordination","drugRate":"reported","severity":"unknown"},{"effect":"Confusion","drugRate":"reported","severity":"unknown"},{"effect":"Restlessness","drugRate":"reported","severity":"unknown"},{"effect":"Excitation","drugRate":"reported","severity":"unknown"},{"effect":"Nervousness","drugRate":"reported","severity":"unknown"},{"effect":"Tremor","drugRate":"reported","severity":"unknown"},{"effect":"Irritability","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesias","drugRate":"reported","severity":"unknown"},{"effect":"Neuritis","drugRate":"reported","severity":"unknown"},{"effect":"Convulsions","drugRate":"reported","severity":"unknown"},{"effect":"Euphoria","drugRate":"reported","severity":"unknown"},{"effect":"Hallucinations","drugRate":"reported","severity":"unknown"},{"effect":"Hysteria","drugRate":"reported","severity":"unknown"},{"effect":"Faintness","drugRate":"reported","severity":"unknown"},{"effect":"Allergic manifestation of rash and edema","drugRate":"reported","severity":"unknown"},{"effect":"Excessive perspiration","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Photosensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Acute labyrinthitis","drugRate":"reported","severity":"unknown"},{"effect":"Blurred vision","drugRate":"reported","severity":"unknown"},{"effect":"Diplopia","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"},{"effect":"Tinnitus","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Palpitation","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Extrasystoles","drugRate":"reported","severity":"unknown"}],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic idiopathic constipation","Hypertensive disorder","Hyperthyroidism","Ocular hypertension","Peptic ulcer","Retention of urine"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyp","Geriatric use":"Clinical studies of cyproheptadine HCl tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal,","Paediatric use":"Safety and effectiveness in pediatric patients below the age of two years have not been established. (See and .) Pediatric Use: CONTRAINDICATIONS, Newborn or Premature Infants WARNINGS, Children."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0500/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$18","description":"CYPROHEPTADINE 2 MG/5 ML SOLN","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T15:52:25.430439","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CYPROHEPTADINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:03.208468+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:08.913496+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:35:02.337806+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYPROHEPTADINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:09.242924+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.588303+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.588328+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:10.851191+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:10.398403+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1716/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:10.044995+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA088212","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:01.588331+00:00"}},"allNames":"cyproheptadine hydrochloride","offLabel":[],"synonyms":["periactin","cyproheptadine","cyproheptadine hydrochloride","cycloheptadine","periactinol","cyproheptadine HCl"],"timeline":[{"date":"1961-10-17","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1961-10-17","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Cyproheptadine Hydrochloride","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Dermatographic urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Sneezing","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","isPrimary":true,"activityType":"Ki","activityValue":10.222},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HRH4","source":"DrugCentral","target":"Histamine H4 receptor","protein":"Histamine H4 receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"}],"modality":"Small Molecule","drugClass":"cyproheptadine","explanation":"","oneSentence":"","technicalDetail":"Cyproheptadine acts as a competitive antagonist at the histamine H1 receptor, inhibiting the binding of histamine and subsequent downstream signaling pathways that contribute to allergic responses."},"commercial":{"launchDate":"1961","_launchSource":"DrugCentral (FDA 1961-10-17, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/765","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYPROHEPTADINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYPROHEPTADINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:25:52.616563","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:13.590676+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"antazoline","drugSlug":"antazoline","fdaApproval":"1990-04-30","relationship":"same-class"},{"drugName":"triprolidine","drugSlug":"triprolidine","fdaApproval":"1983-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azatadine","drugSlug":"azatadine","fdaApproval":"1977-03-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-class"},{"drugName":"terfenadine","drugSlug":"terfenadine","fdaApproval":"","relationship":"same-class"},{"drugName":"loratadine","drugSlug":"loratadine","fdaApproval":"1993-04-12","genericCount":29,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketotifen","drugSlug":"ketotifen","fdaApproval":"1999-07-02","patentExpiry":"Mar 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"acrivastine","drugSlug":"acrivastine","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"epinastine","drugSlug":"epinastine","fdaApproval":"2003-10-16","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fexofenadine","drugSlug":"fexofenadine","fdaApproval":"1996-07-25","patentExpiry":"Aug 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desloratadine","drugSlug":"desloratadine","fdaApproval":"2001-12-21","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cyproheptadine","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Dermatographic urticaria","source":"DrugCentral","snomedId":7632005,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Sneezing","source":"DrugCentral","snomedId":76067001,"regulator":"FDA"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"}],"offLabel":[{"name":"Muscle spasticity of spinal origin","source":"DrugCentral","drugName":"CYPROHEPTADINE","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"SSRI induced sexual dysfunction","source":"DrugCentral","drugName":"CYPROHEPTADINE","evidenceCount":5,"evidenceLevel":"emerging"},{"name":"Serotonin syndrome","source":"DrugCentral","drugName":"CYPROHEPTADINE","evidenceCount":240,"evidenceLevel":"strong"}],"pipeline":[]},"_fixedFields":["primaryTarget"],"currentOwner":"Merck","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"antazoline","brandName":"antazoline","genericName":"antazoline","approvalYear":"1990","relationship":"same-class"},{"drugId":"triprolidine","brandName":"triprolidine","genericName":"triprolidine","approvalYear":"1983","relationship":"same-class"},{"drugId":"azatadine","brandName":"azatadine","genericName":"azatadine","approvalYear":"1977","relationship":"same-class"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-class"},{"drugId":"terfenadine","brandName":"terfenadine","genericName":"terfenadine","approvalYear":"","relationship":"same-class"},{"drugId":"loratadine","brandName":"loratadine","genericName":"loratadine","approvalYear":"1993","relationship":"same-class"},{"drugId":"ketotifen","brandName":"ketotifen","genericName":"ketotifen","approvalYear":"1999","relationship":"same-class"},{"drugId":"acrivastine","brandName":"acrivastine","genericName":"acrivastine","approvalYear":"1994","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"},{"drugId":"epinastine","brandName":"epinastine","genericName":"epinastine","approvalYear":"2003","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":["COVID-19"],"enrollment":1500,"completionDate":"2030-07-31"},{"nctId":"NCT06751290","phase":"PHASE4","title":"The Use of Cyproheptadine in Pediatric Feeding Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2024-12-30","conditions":["Pediatric Feeding Disorder, Chronic","Avoidant Restrictive Food Intake Disorder"],"enrollment":50,"completionDate":"2026-04-30"},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":["Multiple Myeloma"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT05421416","phase":"PHASE2","title":"Loratadine for the Prevention of G-CSF-related Bone Pain","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-11-28","conditions":["Stem Cell Transplant Complications"],"enrollment":78,"completionDate":"2026-12-01"},{"nctId":"NCT07380178","phase":"NA","title":"The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2025-04-01","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":40,"completionDate":"2025-07-05"},{"nctId":"NCT07300735","phase":"NA","title":"Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-03-01","conditions":["Hematologic Malignancy","Neutropenia","Bone Pain"],"enrollment":88,"completionDate":"2026-07"},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":["Spinal Cord Injuries"],"enrollment":25,"completionDate":"2025-10-30"},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":["Fabry's Disease"],"enrollment":8,"completionDate":"2024-10-25"},{"nctId":"NCT06955741","phase":"PHASE1","title":"A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-05","conditions":["Healthy Volunteer"],"enrollment":46,"completionDate":"2025-09-11"},{"nctId":"NCT06175273","phase":"PHASE2,PHASE3","title":"Pediatric Oncology Nutrition Intervention Trial","status":"COMPLETED","sponsor":"Corey Hawes","startDate":"2024-01-31","conditions":["Pediatric Cancer","Nutrition Related Cancer","Nutrition Aspect of Cancer","Muscle Loss","Malnutrition, Child"],"enrollment":19,"completionDate":"2025-08-04"},{"nctId":"NCT05753774","phase":"NA","title":"Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders","status":"RECRUITING","sponsor":"Biao Zou","startDate":"2022-08-01","conditions":["Functional Gastrointestinal Disorders"],"enrollment":100,"completionDate":"2026-08-01"},{"nctId":"NCT07006181","phase":"NA","title":"Effectiveness of Cyproheptadine Hydrochloride Against Appetite to Improve Children's Nutritional Status","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2024-11-04","conditions":["Appetite Loss"],"enrollment":44,"completionDate":"2025-03-31"},{"nctId":"NCT03593811","phase":"EARLY_PHASE1","title":"Noninvasive Markers of Functional Nausea in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2018-08-03","conditions":["Nausea"],"enrollment":42,"completionDate":"2026-08-31"},{"nctId":"NCT06147622","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2024-04-23","conditions":["Alcohol Use Disorder"],"enrollment":12,"completionDate":"2024-12-31"},{"nctId":"NCT06265077","phase":"PHASE1,PHASE2","title":"Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients","status":"COMPLETED","sponsor":"Noha Mansour","startDate":"2024-02-01","conditions":["Breast Cancer","Filgrastim Adverse Reaction"],"enrollment":58,"completionDate":"2024-10-17"},{"nctId":"NCT01673620","phase":"PHASE3","title":"A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-07-04","conditions":["Allergic Rhinitis"],"enrollment":69,"completionDate":"2012-10-10"},{"nctId":"NCT00423995","phase":"PHASE3","title":"Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-11-01","conditions":["Seasonal Allergic Rhinitis"],"enrollment":379,"completionDate":"2007-03-10"},{"nctId":"NCT00319995","phase":"PHASE3","title":"Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03-01","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":1095,"completionDate":"2006-06-28"},{"nctId":"NCT06531707","phase":"PHASE3","title":"Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-05-20","conditions":["Common Cold"],"enrollment":177,"completionDate":"2025-02-20"},{"nctId":"NCT06396013","phase":"PHASE1","title":"A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Hospital of Traditional Chinese Medicine","startDate":"2024-06-01","conditions":["Plaque Psoriasis"],"enrollment":96,"completionDate":"2026-07-31"},{"nctId":"NCT04108104","phase":"PHASE2","title":"Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2019-11-30","conditions":["Alcohol Use Disorder"],"enrollment":154,"completionDate":"2022-01-31"},{"nctId":"NCT06250400","phase":"PHASE4","title":"Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)","status":"UNKNOWN","sponsor":"Hangzhou Grand Biologic Pharmaceutical, Inc.","startDate":"2024-03-31","conditions":["Chronic Spontaneous Urticaria"],"enrollment":252,"completionDate":"2025-12-31"},{"nctId":"NCT06217367","phase":"PHASE4","title":"Over-the-Counter Antihistamines & Heat Stress","status":"UNKNOWN","sponsor":"Lakehead University","startDate":"2023-12-05","conditions":["Heat Illness","Allergic Rhinitis","Heat Injury","Sudomotor Sympathetic Dysfunction"],"enrollment":16,"completionDate":"2024-06"},{"nctId":"NCT05469165","phase":"PHASE2","title":"Serotonin Receptor Blockers in Ischemic Mitral Regurgitation","status":"RECRUITING","sponsor":"Laval University","startDate":"2023-06-20","conditions":["Ischemic Mitral Regurgitation"],"enrollment":214,"completionDate":"2027-09"},{"nctId":"NCT02418949","phase":"NA","title":"Altering Activation Patterns Post-stroke","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2015-11","conditions":["Stroke","Muscle Spasticity","Hemiparesis"],"enrollment":96,"completionDate":"2023-12"},{"nctId":"NCT05043350","phase":"PHASE2,PHASE3","title":"Combined Antihistaminics Therapy in COVID 19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-09-13","conditions":["Covid19"],"enrollment":214,"completionDate":"2022-07-30"},{"nctId":"NCT04211259","phase":"EARLY_PHASE1","title":"Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization","status":"UNKNOWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-04-18","conditions":["Plasma Cell Myeloma"],"enrollment":70,"completionDate":"2025-06-30"},{"nctId":"NCT05750875","phase":"PHASE4","title":"Gabapentin Versus Loratadine in Uremic Pruritus","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2022-05-01","conditions":["Pruritus","Uremia","Chronic Kidney Diseases"],"enrollment":64,"completionDate":"2022-10-31"},{"nctId":"NCT04248712","phase":"PHASE2","title":"Antihistamines in Eosinophilic Esophagitis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-07-10","conditions":["Eosinophilic Esophagitis"],"enrollment":1,"completionDate":"2021-12-31"},{"nctId":"NCT05087381","phase":"PHASE4","title":"Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2021-10-01","conditions":["Treatment Efficacy"],"enrollment":1200,"completionDate":"2022-06-21"},{"nctId":"NCT01055756","phase":"PHASE3","title":"Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis","status":"WITHDRAWN","sponsor":"Azidus Brasil","startDate":"2010-01","conditions":["Allergic Rhinitis"],"enrollment":0,"completionDate":"2010-06"},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":["Kidney Transplant"],"enrollment":290,"completionDate":"2021-07-23"},{"nctId":"NCT05265910","phase":"PHASE4","title":"A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Andover Research Eye Institute","startDate":"2021-12-14","conditions":["Allergic Conjunctivitis"],"enrollment":58,"completionDate":"2022-04-23"},{"nctId":"NCT03004131","phase":"PHASE4","title":"MP-AzeFlu Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2017-01-07","conditions":["Seasonal Allergic Rhinitis"],"enrollment":82,"completionDate":"2017-03-29"},{"nctId":"NCT05243706","phase":"PHASE3","title":"Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":["Vinca Alkaloid Adverse Reaction"],"enrollment":90,"completionDate":"2023-12-30"},{"nctId":"NCT03855228","phase":"PHASE3","title":"Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1995-03-01","conditions":["Rhinitis, Allergic"],"enrollment":704,"completionDate":"1995-08-07"},{"nctId":"NCT00979901","phase":"PHASE3","title":"Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03","conditions":["Seasonal Allergic Rhinitis"],"enrollment":1577,"completionDate":"2000-05"},{"nctId":"NCT00963599","phase":"PHASE3","title":"Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1999-09","conditions":["Seasonal Allergic Rhinitis"],"enrollment":907,"completionDate":"1999-11"},{"nctId":"NCT05190627","phase":"PHASE2","title":"Effect of Loratadine in Lymphangioleiomyomatosis","status":"UNKNOWN","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","startDate":"2021-11-01","conditions":["Lymphangioleiomyomatosis"],"enrollment":62,"completionDate":"2023-12-30"},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":["Asthma in Children"],"enrollment":21,"completionDate":"2019-10-03"},{"nctId":"NCT04979221","phase":"PHASE3","title":"Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-07-26","conditions":["COVID-19 Pneumonia"],"enrollment":274,"completionDate":"2022-02-28"},{"nctId":"NCT04876573","phase":"PHASE2","title":"Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19","status":"UNKNOWN","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2021-06-01","conditions":["Viral Pneumonia","COVID-19 Pneumonia","Serotonin Syndrome","Platelet Dysfunction"],"enrollment":60,"completionDate":"2022-01-31"},{"nctId":"NCT04820751","phase":"PHASE3","title":"Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial","status":"UNKNOWN","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2021-04-10","conditions":["Viral Pneumonia","Serotonin Syndrome","Platelet Dysfunction"],"enrollment":200,"completionDate":"2022-01-01"},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":["Progressive Multiple Sclerosis"],"enrollment":24,"completionDate":"2021-03-01"},{"nctId":"NCT04162795","phase":"PHASE4","title":"A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-11-12","conditions":["Allergic Rhinitis"],"enrollment":468,"completionDate":"2019-11-13"},{"nctId":"NCT03883386","phase":"PHASE2","title":"Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2019-06-24","conditions":["Bone Pain"],"enrollment":3,"completionDate":"2019-10-18"},{"nctId":"NCT03196531","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-11-07","conditions":["Healthy"],"enrollment":108,"completionDate":"2018-03-31"},{"nctId":"NCT02568007","phase":"PHASE4","title":"Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2015-12","conditions":["Feeding Behaviors"],"enrollment":4,"completionDate":"2016-08"},{"nctId":"NCT03443843","phase":"PHASE4","title":"A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-21","conditions":["Rhinitis, Allergic"],"enrollment":82,"completionDate":"2018-05-11"},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":1025,"completionDate":"2018-11-19"},{"nctId":"NCT02392039","phase":"EARLY_PHASE1","title":"Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-14","conditions":["Lymphoma"],"enrollment":1,"completionDate":"2018-04-04"},{"nctId":"NCT03517930","phase":"PHASE1","title":"A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-04-17","conditions":["Clinical Pharmacology"],"enrollment":52,"completionDate":"2018-07-20"},{"nctId":"NCT03517943","phase":"PHASE1","title":"A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-04-24","conditions":["Clinical Pharmacology"],"enrollment":29,"completionDate":"2018-08-30"},{"nctId":"NCT03640273","phase":"PHASE2","title":"Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2017-11-23","conditions":["Allergic Rhinitis","Adverse Drug Event","Quality of Life"],"enrollment":72,"completionDate":"2018-06-24"},{"nctId":"NCT02339714","phase":"PHASE2","title":"Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis","status":"COMPLETED","sponsor":"Zhao Hong","startDate":"2015-03","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":98,"completionDate":"2018-06"},{"nctId":"NCT02305979","phase":"","title":"Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-12","conditions":["Leukemia","Lymphoma"],"enrollment":61,"completionDate":"2017-09"},{"nctId":"NCT02513290","phase":"PHASE4","title":"Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine","status":"COMPLETED","sponsor":"Universidade do Sul de Santa Catarina","startDate":"2013-08","conditions":["Allergic Rhinitis"],"enrollment":73,"completionDate":"2014-08"},{"nctId":"NCT03376594","phase":"PHASE2","title":"Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2017-07-30","conditions":["Allergic Rhinitis"],"enrollment":60,"completionDate":"2018-03-31"},{"nctId":"NCT01451996","phase":"PHASE4","title":"The Efficacy of Claritin in Healthy Subjects","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-10","conditions":["Healthy"],"enrollment":340,"completionDate":"2012-12"},{"nctId":"NCT01712009","phase":"PHASE2","title":"NOLAN: Naproxen or Loratadine and Neulasta","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-01","conditions":["Bone Pain in Stage I - III Breast Cancer"],"enrollment":600,"completionDate":"2015-03-18"},{"nctId":"NCT03372473","phase":"PHASE3","title":"Montelukast and Loratadine in Children With Asthma","status":"COMPLETED","sponsor":"Innovacion y Desarrollo de Estrategias en Salud","startDate":"2016-01-10","conditions":["Asthma in Children"],"enrollment":80,"completionDate":"2017-06-30"},{"nctId":"NCT02576808","phase":"PHASE2","title":"Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis","status":"COMPLETED","sponsor":"Thai Traditional Medical Knowledge Fund","startDate":"2015-10","conditions":["Rhinitis,Allergic"],"enrollment":80,"completionDate":"2017-10"},{"nctId":"NCT03151720","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-06-01","conditions":["Healthy"],"enrollment":28,"completionDate":"2017-07-08"},{"nctId":"NCT01675050","phase":"PHASE2","title":"A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2012-08","conditions":["Functional Abdominal Pain"],"enrollment":4,"completionDate":"2013-08"},{"nctId":"NCT02932774","phase":"PHASE4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2001-03","conditions":["Allergic Rhinitis","Hay Fever","SAR","Rhinitis, Allergic, Seasonal"],"enrollment":683,"completionDate":"2001-07"},{"nctId":"NCT00730912","phase":"PHASE4","title":"Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-06","conditions":["Perennial Allergic Rhinitis"],"enrollment":261,"completionDate":"2008-12"},{"nctId":"NCT00946608","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets","status":"COMPLETED","sponsor":"Sandoz","startDate":"2005-06","conditions":["Allergy"],"enrollment":30,"completionDate":"2005-08"},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":["Rhinoconjunctivitis","Rhinitis","Conjunctivitis","Allergy"],"enrollment":439,"completionDate":"2009-09"},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":["Rhinoconjunctivitis","Rhinitis","Conjunctivitis","Allergy"],"enrollment":345,"completionDate":"2009-09"},{"nctId":"NCT02593747","phase":"PHASE1","title":"To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-12","conditions":["Histamine H1 Antagonists, Non-Sedating"],"enrollment":54,"completionDate":"2016-03"},{"nctId":"NCT01390441","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":["Rheumatoid Arthritis"],"enrollment":100,"completionDate":"2014-04"},{"nctId":"NCT02653339","phase":"NA","title":"Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-06","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":180,"completionDate":"2018-08"},{"nctId":"NCT01228630","phase":"PHASE3","title":"Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2011-08","conditions":["Perennial Allergic Rhinitis"],"enrollment":156,"completionDate":"2012-05"},{"nctId":"NCT01519856","phase":"","title":"PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2009-06","conditions":["Parkinson's Disease"],"enrollment":908,"completionDate":"2015-02"},{"nctId":"NCT01688570","phase":"EARLY_PHASE1","title":"Mechanisms of Neuromuscular Fatigue Post Stroke","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-08","conditions":["Stroke"],"enrollment":27,"completionDate":"2015-05"},{"nctId":"NCT02007434","phase":"PHASE3","title":"Patient Experience Study of Deoxycholic Acid Injection","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2013-12","conditions":["Moderate or Severe Submental Fullness"],"enrollment":84,"completionDate":"2014-06"},{"nctId":"NCT01132547","phase":"PHASE3","title":"Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2010-06","conditions":["Cancer"],"enrollment":22,"completionDate":"2014-01"},{"nctId":"NCT01538693","phase":"NA","title":"Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury","status":"COMPLETED","sponsor":"T. George Hornby","startDate":"2011-12","conditions":["Spinal Cord Injury"],"enrollment":30,"completionDate":"2015-05"},{"nctId":"NCT00963573","phase":"PHASE4","title":"Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-09","conditions":["Rhinitis"],"enrollment":100,"completionDate":"2006-11"},{"nctId":"NCT01940978","phase":"PHASE4","title":"A Study of Combination Therapy in Children With ADHD","status":"COMPLETED","sponsor":"Douglas Sears","startDate":"2014-03","conditions":["ADHD","Attention Deficit Hyperactivity Disorder","Attention Deficit Disorder With Hyperactivity","Mental Disorders Diagnosed in Childhood","Attention Deficit and Disruptive Behavior Disorders"],"enrollment":99,"completionDate":"2015-03"},{"nctId":"NCT01413958","phase":"PHASE3","title":"Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-08","conditions":["Seasonal Allergic Rhinitis"],"enrollment":575,"completionDate":"2011-10"},{"nctId":"NCT01469234","phase":"PHASE4","title":"A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":["Rhinitis"],"enrollment":255,"completionDate":"2011-11"},{"nctId":"NCT01330017","phase":"PHASE2","title":"Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":["Rhinitis","Seasonal Rhinitis"],"enrollment":539,"completionDate":"2011-06"},{"nctId":"NCT00762983","phase":"","title":"Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":["Rhinitis, Allergic, Seasonal","Rhinitis, Allergic, Perennial","Urticaria","Pruritus"],"enrollment":1003,"completionDate":"2009-02"},{"nctId":"NCT00949117","phase":"PHASE2","title":"Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2009-09","conditions":["Leukemia","Lymphoma","Malnutrition","Myelodysplastic Syndromes","Unspecified Childhood Solid Tumor, Protocol Specific","Weight Changes"],"enrollment":9,"completionDate":"2011-11"},{"nctId":"NCT00066248","phase":"PHASE2","title":"Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2003-06","conditions":["Brain Tumor","Central Nervous System Tumors","Cachexia","Leukemia","Lymphoma","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Diseases","Unspecified Childhood Solid Tumor, Protocol Specific"],"enrollment":70,"completionDate":"2007-08"},{"nctId":"NCT01076283","phase":"PHASE2","title":"A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking","status":"COMPLETED","sponsor":"Brown University","startDate":"2009-12","conditions":["Alcoholism"],"enrollment":14,"completionDate":"2010-05"},{"nctId":"NCT00561717","phase":"PHASE4","title":"A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":["Seasonal Allergic Rhinitis"],"enrollment":70,"completionDate":"2008-02"},{"nctId":"NCT01311336","phase":"PHASE2","title":"Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2011-05","conditions":["Pegfilgrastim-induced Back and Leg Pain"],"enrollment":55,"completionDate":"2013-06"},{"nctId":"NCT01509885","phase":"","title":"Cyproheptadine and Chlorpromazine Effects on Spasticity","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2010-07","conditions":["Spinal Cord Injuries","Muscle Spasticity"],"enrollment":20,"completionDate":"2012-11"},{"nctId":"NCT00449072","phase":"PHASE4","title":"Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":["Rhinitis, Allergic, Perennial"],"enrollment":299,"completionDate":"2011-10"},{"nctId":"NCT01007864","phase":"PHASE3","title":"Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2010-01","conditions":["Idiopathic Parkinson's Disease"],"enrollment":80,"completionDate":"2011-12"},{"nctId":"NCT00481676","phase":"PHASE2","title":"Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":["Chronic Urticaria"],"enrollment":49,"completionDate":"2009-04"},{"nctId":"NCT01314989","phase":"PHASE4","title":"Cyproheptadine as an Appetite Stimulant","status":"UNKNOWN","sponsor":"St. Justine's Hospital","startDate":"2010-12","conditions":["Failure to Thrive"],"enrollment":20,"completionDate":"2012-01"},{"nctId":"NCT01295450","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex","status":"UNKNOWN","sponsor":"MDCPharma Produtos Farmaceuticos LTDA","startDate":"2011-04","conditions":["Lack of Appetite","Anorexia"],"enrollment":74,"completionDate":"2011-08"},{"nctId":"NCT00837915","phase":"NA","title":"Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2002-06","conditions":["Healthy"],"enrollment":40,"completionDate":"2002-11"},{"nctId":"NCT00776217","phase":"NA","title":"Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-06","conditions":["Healthy"],"enrollment":80,"completionDate":"2006-09"},{"nctId":"NCT00776282","phase":"NA","title":"Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-07","conditions":["Healthy"],"enrollment":80,"completionDate":"2006-09"},{"nctId":"NCT00721331","phase":"PHASE1","title":"A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Zalicus","startDate":"2008-07","conditions":["Atopic Dermatitis"],"enrollment":20,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Solution, Syrup, Tablet","formulations":[{"form":"SOLUTION","route":"ORAL","productName":"CYPROHEPTADINE HYDROCHLORIDE"},{"form":"SOLUTION","route":"ORAL","productName":"Cyproheptadine Hydrochloride"},{"form":"SYRUP","route":"ORAL","productName":"CYPROHEPTADINE"},{"form":"SYRUP","route":"ORAL","productName":"Cyproheptadine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"CYPROHEPTADINE HYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"Cyproheptadine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"cyproheptadine hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Cyproheptadine Hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147793","MMSL":"2249","NDDF":"001537","UNII":"2YHB6175DO","VUID":"4019701","CHEBI":"CHEBI:4046","VANDF":"4017931","INN_ID":"872","RXNORM":"104592","UMLSCUI":"C0010620","chemblId":"CHEMBL1716","ChEMBL_ID":"CHEMBL516","KEGG_DRUG":"D02234","DRUGBANK_ID":"DB00434","PDB_CHEM_ID":" C7H","PUBCHEM_CID":"2913","SNOMEDCT_US":"15352003","IUPHAR_LIGAND_ID":"277","SECONDARY_CAS_RN":"41354-29-4","MESH_DESCRIPTOR_UI":"D003533"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Merck","relationship":"Current Owner"}],"publicationCount":2503,"therapeuticAreas":["Dermatology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AX02","allCodes":["R06AX02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":31,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Am Therap","Appco","Ascot","Chartwell Molecular","Chartwell Rx","Duramed Pharms Barr","Halsey","Heritage Pharma","Ingenus Pharms Llc","Kenton","Kv Pharm","Md Pharm","Morton Grove","Mountain","Mylan","Naska","Patrin","Pharm Assoc","Pioneer Pharms","Pliva","Quagen","Regcon Holdings","Rising","St John Pharm","Strides Pharma Intl","Superpharm","Tris Pharma Inc","Vitarine","Watson Labs","Zydus Pharms"],"status":"approved","companyName":"Merck","companyId":"","modality":"Small molecule","firstApprovalDate":"1961","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1961-10-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-09-30T00:00:00.000Z","mah":"MOUNTAIN","brand_name_local":null,"application_number":"ANDA040537"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-11-29T00:00:00.000Z","mah":"APPCO","brand_name_local":null,"application_number":"ANDA206553"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-04-11T00:00:00.000Z","mah":"STRIDES PHARMA INTL","brand_name_local":null,"application_number":"ANDA209172"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-16T00:00:00.000Z","mah":"ST JOHN PHARM","brand_name_local":null,"application_number":"ANDA209108"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-12-21T00:00:00.000Z","mah":"TRIS PHARMA INC","brand_name_local":null,"application_number":"ANDA205431"},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"18.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:13.590676+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}